Organization
National Institutes of Health All of Us Research Program
35 abstracts
Abstract
Advancing team science and health equity in clinical oncology using the All of Us Research Program dataset.Org: National Institutes of Health All of Us Research Program, Delta Research and Educational Foundation (DREF),
Abstract
Inhibition of AR and DNA-PK for radio-sensitization of AR-driven cancers.Org: Cancer Research UK Cambridge Institute, Artios Pharma, National Institutes of Health All of Us Research Program, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, AstraZeneca,
Abstract
Association of a polygenic risk score with risk of abnormal ultrasound findings and ovarian cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.Org: National Cancer Institute, Vilnius, Lithuania, American Cancer Society, National Institutes of Health All of Us Research Program,
Abstract
Representation of Hispanics with liver cancer in oncology genotype databases.Org: Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program,
Abstract
PRGN-2012, a novel gorilla adenovirus-based immunotherapy, provides the first treatment that leads to complete and durable responses in recurrent respiratory papillomatosis patients.Org: National Cancer Institute, Vilnius, Lithuania, Center for Immune-Oncology, Center for Cancer Research, National Cancer Institute, Precigen, Inc., National Institutes of Health All of Us Research Program,
Abstract
Identifying digital pathology imaging based biomarkers of checkpoint inhibitor response in non-small cell lung cancer.Org: National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Bethesda, VA, Bethesda, MD, SUNY Upstate Medical University,
Abstract
Tazemetostat in combination with topotecan and pembrolizumab in patients with recurrent small cell lung cancer.Org: Fox Chase Cancer Center, Temple University Hospital, Philadelphia, PA, Philadelphia, PA, National Cancer Center Hospital East, Kashiwa, Japan, Shinjuku-Ku, Japan,
Abstract
Altering the gut microbiome and TME in advanced liver cancers: A phase II study of nivolumab, tadalafil, and oral vancomycin in refractory HCC or liver-dominant metastatic CRC or PDAC.Org: Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program,
Abstract
Molecular profiling of ctDNA from NCI-MATCH patients enrolled for treatment with mTOR1/2 inhibitor sapanisertib (arm M) and the Hedgehog pathway inhibitor vismodegib (arm T).Org: Illumina, Inc., Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, National Cancer Institute, Vilnius, Lithuania, Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD,
Abstract
Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).Org: Laboratory of Transplantation Immunotherapy, Cellular and Molecular Therapeutics Branch, NHLBI, NIH, Department of Surgery, Loyola University Chicago, Department of Transfusion Medicine, Clinical Center, NIH, Laboratory of Transplantation Immunotherapy, Cellular and Molecular Therapeutics Branch, National Heart Lung and Blood Institute, National Institutes of Health, National Institutes of Health Clinical Center Department of Laboratory Medicine,
Abstract
Prediction of cancer treatment response from histopathology images through imputed transcriptomics.Org: Pangea Biomed, University of Pittsburgh, Pittsburgh, PA, Sheba Medical Center at Tel-Hashomer, University of Colorado School of Medicine, Department of Oncology and Cancer Research UK Cambridge Institute,
Abstract
Genomic characterization of somatic mutations by race and ethnicity in pancreatic cancer defined through AACR project GENIE.Org: Laboratory of Molecular Biology, NCI, NIH, Bethesda, MD, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program,
Abstract
Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.Org: City of Hope National Medical Center, Fred Hutchiinson Cancer Research Center, SWOG Statistics and Data Management Center, Seattle, WA, Johns Hopkins University School of Medicine, University of Pennsylvania,
Abstract
Molecular classification of cancer site of origin and lineage.Org: National Institutes of Health All of Us Research Program, National Cancer Institute, Vilnius, Lithuania, Bethesda, MD, Department of Human Oncology, University of Wisconsin, Madison, WI,
Abstract
Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome.Org: Pangea Biomed, National Cancer Institute, Vilnius, Lithuania, Cancer Data Science Laboratory (CDSL), National Institutes of Health All of Us Research Program, Women’s Malignancies Branch,
Abstract
The role of innate immune system in modulating CHK1 inhibitor (CHK1i) response in BRCA wild-type (BRCAwt), platinum-resistant high-grade serous ovarian cancer (PR-HGSOC): Exploratory analysis from a phase II study of CHK1i prexasertib.Org: Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Bethesda, MD,
Abstract
A study of prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging (18F-DCFPyL).Org: Genitourinary Malignancies Branch, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute,
Abstract
Mismatch repair deficiency and microsatellite instability-high in urothelial carcinoma: A systematic review and meta-analysis.Org: National Cancer Institute, Vilnius, Lithuania, Memorial Sloan Kettering Cancer Center, National Institutes of Health All of Us Research Program,
Abstract
A phase I study of bintrafusp alfa and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic genitourinary (GU) malignancies.Org: Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, NYU Langone Laura and Isaac Perlmutter Cancer Center, Genitourinary Malignancies Branch,
Abstract
Phase II study of crizotinib in patients with MET amplification and MET exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2.Org: St. James’s Hospital, Dana-Farber Cancer Institute, University of Texas MD Anderson Cancer Center, Jefferson Kimmel Cancer Center at Jefferson Health, NCI,
Abstract
Associations between psychosocial and lifestyle factors and biological age acceleration among long-term survivors of childhood cancer: A prospective study from the St. Jude Lifetime Cohort.Org: National Cancer Institute, Vilnius, Lithuania, Rockville, MD, St. Jude Children's Research Hospital, Memphis, TN, Columbia University - Mailman School of Public Health,
Abstract
Long-term outcomes in a population-based cohort of 2,967 uveal melanoma patients clinically tested with the 15-gene expression profile: A collaborative study with the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program Registries.Org: Castle Biosciences, Inc., Friendswood, TX, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Rockville, MD,
Abstract
Integrating the 31-gene expression profile test into clinical decision-making to guide risk-aligned care decisions for patients with stage I-III cutaneous melanoma: NCI-SEER Analysis.Org: Desert Surgical Oncology, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Castle Biosciences, Castle Biosciences, Inc.,
Abstract
B7H3 expression in sarcoma.Org: Northwestern Memorial Hospital, Chicago, IL, Chicago, IL, Northwestern University-Feinberg School of Medicine, University of Washington and Fred Hutchinson Cancer Research Centre, Seattle, WA,
Abstract
Phase II trial evaluating nivolumab in patients with recurrent IDH-mutant gliomas with and without hypermutation phenotype.Org: Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Bethesda, MD,
Abstract
Older adults (OA) in clinical trials: Where are they? Representation of OA in clinical trials conducted at the National Cancer Institute (NCI) Clinical Center.Org: Genitourinary Malignancies Branch, CCRT/The Caroline Foundation, NCI, Nihon Medi-Physics, Medical Oncology Service,
Abstract
Comprehensive Outcomes for After Cancer Health: COACH.Org: University of Nebraska Medical Center, Nebraska Medicine Bellevue, University of Nebraska Medical Center College of Nursing, The Ohio State University - James Cancer Hospital, Pack Health, A Quest Diagnostics Company,
Abstract
A phase II study of tremelimumab, durvalumab, and bevacizumab in advanced biliary tract cancers.Org: Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Laboratory of Pathology, NCI, NIH, Bethesda, MD,
Abstract
Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.Org: Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, TX, Dana-Farber Cancer Institute, Boston, MA,
Abstract
Association of surgery and radiotherapy with risk of thoracic soft tissue sarcoma among older survivors of breast cancer.Org: National Institutes of Health All of Us Research Program, Bethesda, VA, MD Anderson Cancer Center, National Cancer Institute, Vilnius, Lithuania, NCI/NIH,
Abstract
Incidence of hepatocellular cancer in India: Analysis of population based cancer registry data.Org: National Institutes of Health All of Us Research Program, University of Kentucky, Lexington, KY, Markey Cancer Center, University of Kentucky, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, Malankara Orthodox Syrian Church Medical College and Hospital,
Abstract
Mass cytometry immune profiling to detect signatures of clinical activity of bintrafusp alfa (BA) in patients with advanced non-small cell lung cancer (NSCLC).Org: Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Teiko Bio,
Abstract
Primary care utilization and cardiovascular screening in adult-aged survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).Org: Cancer and Blood Disorders Center, Seattle Children's Hospital, University of Alberta, University of Washington and Fred Hutchinson Cancer Research Centre, St. Jude Children's Research Hospital,
Abstract
A funder-based comparison of global oncology research led by NCI-designated cancer centers: Results from the 2021 Global Oncology Survey.Org: Center for Global Health, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Rockville, MD, Indiana University Melvin and Bren Simon Comprehensive Cancer Center,
Abstract
ANGIOGRAPHIC PROGRESSION OF DISEASE IN LARGE-VESSEL VASCULITISOrg: National Institutes of Health All of Us Research Program, Georgetown University Hospital, Washington, DC,